Biotech stocks ready for more Covid-19 results in first quarter

Potential approval of an Alzheimer’s medicine, new gene therapy data and more late-stage clinical trial results for Covid-19 vaccines will keep momentum up for biotech stocks in the next three months.

Photo: Issei Kato/REUTERS / X90003

The benchmark Nasdaq Biotech Index has climbed 26% this year, compared with a 15% gain in the S&P 500 Index, pointing to no let-up in market-moving drug trial data even during the pandemic.

While the index hit a bump this week amid worries of delays in distribution of the two U.S.-approved inoculations, investors are on the lookout as a second group of vaccine developers race to test shots, including those from Novavax, Johnson & Johnson and partners Glaxosmithkline and Sanofi.

Read the whole article

Get 14 days free access.
No credit card required.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

"Real world" patient data documents the long-term effects of ALK vaccines

In the largest study ever of its kind, patient data from the "real world" documents the long-term effects of up to nine years of ALK vaccines. Up until now, it has not been possible to demonstrate these in ordinary clinical studies where the follow-up period is shorter, and the new knowledge could be a turning point in ALK's dialog about prices and subsidies with authorities and payers. 

Further reading

Latest news

See all jobs